CROSSLIFE TECHNOLOGIES INC. — Department of Health and Human Services SBIR Phase I: NIAID

Description

Rapid Point of Care RNA Diagnostic for Dengue Infection CrossLife Technologies IncProject Summary Abstract Dengue virusesDENVare one of the most dangerous and significant pathogens in the worldand there aremillion cases of dengue virus infections per yearmostly in Latin America and Southeast AsiaThese mosquito borne viruses cause periodic explosive epidemics in many tropical and sub tropical countriesCrossLife technologiesandaposdengue diagnostic is being developed to detect dengue infection early at the point of care so that patients can be treated effectivelyEarly and rapid detection of dengue virusDENVinfection during the febrile period is crucial for proper patient management and containment of the diseaseHowevercurrent methods for early detection of dengue involve the use of RT PCR instruments in the laboratorywhich may not be available in areas where dengue is endemicand which may be too slowCrossLife Technologies proposed to develop a Template Assisted Rapid AssayTARAdiagnostics for detection of dengue viruses in human bloodTARA dengue diagnostic will detect dengue inminutes on a paper strip at the point of carePOCso that patients can be treated rapidly and at low costThis innovative technology will provide PCR lessinstrumentation freelow costdisposablerapid and sensitive POC dengue diagnostics directly from whole blood samples Rapid Point of Care RNA Diagnostic for Dengue Infection CrossLife Technologies IncProject Narrative Dengue fever is considered to be one of the most significant public health problems with a huge economic impactwithmillion infections per year world wideWe propose the development and commercialization of a rapidpoint of care diagnostic for early detection of dengue without the need for laboratory instrumentation which may not be available in many resource limited settings where dengue is endemic